Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P F Conte

Showing results (151-160 of 200) with videos related to

Pageof 20
Sort By:
British Journal of Cancer|April 20, 2006
Epirubicin/paclitaxel/etoposide in extensive-stage small-cell lung cancer: a phase I-II studyC Tibaldi, T Prochilo, F Russo, et al.
Tumori|March 18, 1999
Suramin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in metastatic colorectal cancer patients resistant to 5-FU+LV-based chemotherapyA Falcone, E Pfanner, I Brunetti, et al.
British Journal of Cancer|January 1, 1995
Mitomycin-ifosfamide-cisplatinum (MIP) vs MIP-interferon vs cisplatinum-carboplatin in metastatic non-small-cell lung cancer: a FONICAP randomised phase II study. Italian Lung Cancer Task ForceA Ardizzoni, G F Addamo, E Baldini, et al.
Breast Cancer Research and Treatment|November 2, 2001
Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II studyP F Conte, A Gennari, S Donati, et al.
British Journal of Cancer|September 16, 2010
Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapyC Bengala, S Bettelli, F Bertolini, et al.
British Journal of Cancer|August 8, 2024
Correction to: Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapyC Bengala, S Bettelli, F Bertolini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 1, 1997
Maximum tolerable doses of intravenous zidovudine in combination with 5-fluorouracil and leucovorin in metastatic colorectal cancer patients. Clinical evidence of significant antitumor activity and enhancement of zidovudine-induced DNA single strand breaks in peripheral nuclear blood cellsA Falcone, M Lencioni, I Brunetti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 8, 2001
Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patientsA Di Paolo, R Danesi, A Falcone, et al.
Bone Marrow Transplantation|May 24, 2005
High-dose chemotherapy with autologous haemopoietic support for advanced ovarian cancer in first complete remission: retrospective analysis from the Solid Tumour Registry of the European Group for Blood and Marrow Transplantation (EBMT)C Bengala, V Guarneri, J Ledermann, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 4, 2003
Accelerated versus standard cyclophosphamide, epirubicin and 5-fluorouracil or cyclophosphamide, methotrexate and 5-fluorouracil: a randomized phase III trial in locally advanced breast cancerE Baldini, G Gardin, P G Giannessi, et al.
Pageof 20

Showing results (151-160 of 200) with videos related to

Sort By:
Pageof 20
British Journal of Cancer|April 20, 2006
Epirubicin/paclitaxel/etoposide in extensive-stage small-cell lung cancer: a phase I-II studyC Tibaldi, T Prochilo, F Russo, et al.
Tumori|March 18, 1999
Suramin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in metastatic colorectal cancer patients resistant to 5-FU+LV-based chemotherapyA Falcone, E Pfanner, I Brunetti, et al.
British Journal of Cancer|January 1, 1995
Mitomycin-ifosfamide-cisplatinum (MIP) vs MIP-interferon vs cisplatinum-carboplatin in metastatic non-small-cell lung cancer: a FONICAP randomised phase II study. Italian Lung Cancer Task ForceA Ardizzoni, G F Addamo, E Baldini, et al.
Breast Cancer Research and Treatment|November 2, 2001
Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II studyP F Conte, A Gennari, S Donati, et al.
British Journal of Cancer|September 16, 2010
Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapyC Bengala, S Bettelli, F Bertolini, et al.
British Journal of Cancer|August 8, 2024
Correction to: Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapyC Bengala, S Bettelli, F Bertolini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 1, 1997
Maximum tolerable doses of intravenous zidovudine in combination with 5-fluorouracil and leucovorin in metastatic colorectal cancer patients. Clinical evidence of significant antitumor activity and enhancement of zidovudine-induced DNA single strand breaks in peripheral nuclear blood cellsA Falcone, M Lencioni, I Brunetti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 8, 2001
Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patientsA Di Paolo, R Danesi, A Falcone, et al.
Bone Marrow Transplantation|May 24, 2005
High-dose chemotherapy with autologous haemopoietic support for advanced ovarian cancer in first complete remission: retrospective analysis from the Solid Tumour Registry of the European Group for Blood and Marrow Transplantation (EBMT)C Bengala, V Guarneri, J Ledermann, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 4, 2003
Accelerated versus standard cyclophosphamide, epirubicin and 5-fluorouracil or cyclophosphamide, methotrexate and 5-fluorouracil: a randomized phase III trial in locally advanced breast cancerE Baldini, G Gardin, P G Giannessi, et al.
Pageof 20